Articles related to CME

The Evolution of Radiation Therapy Explore the evolution of radiation therapy with Dr. Heath Skinner and understand the advancements in 3DCRT, IMRT/VMAT, proton therapy, stereotactic radiation, and brachytherapy. Dr. Heath D. Skinner, esteemed chair and medical director of the Department of Radiation Oncology at UPMC Hillman Cancer Center, delves into the dynamic and transformative world of radiation oncology in this enlightening Continuing Medical Education (CME) activity. A noted specialist in the treatment of head, neck, and lung cancer, Dr. Skinner’s commitment to advancing clinical research underscores his discussions, which aim to educate and inform on the significant advancements in radiation therapy over recent decades. The CME activity is designed as a comprehensive examination of the evolution of radiation therapy. Dr. Skinner outlines a clear trajectory of progress, highlighting the development from conventional three-dimensional conformal radiation therapy (3DCRT) to more sophisticated techniques such as intensity-modulated radiation therapy/volumetric-modulated arc therapy (IMRT/VMAT), and further to the precision of proton therapy. These techniques, each with unique advantages, have shaped modern oncology practices and offer promising improvements in patient outcomes. Further delving into the field, Dr. Skinner also elucidates the intricacies of stereotactic radiation and brachytherapy as additional pillars in the modern cancer treatment paradigm. […]

NEW YORK CITY | THE GLASSHOUSE CHELSEASATURDAY, JUNE 24, 2023 In a comprehensive in-person setting, psychiatrists will get current, clinically relevant, and practice-based updates. This full-day conference will feature interesting presentations conducted by renowned thought leaders in schizophrenia, postpartum depression, major depressive disorder, ADHD, and addiction. Each session will include a patient perspective to ensure professionals obtain practical, real-world understanding.

Racial affinity group caucusing is explained and proposed as a component of the medical education curriculum for its potential value in dismantling the systems that produce inequities.

This educational program aims to improve the knowledge and comprehension of the clinical trial and real-world evidence for the CDK4/6i class among HCPs. A greater percentage of patients with HR+/HER2 metastatic breast cancer (mBC) will have access to this therapeutic option by filling care gaps linked to CDK4/6i usage. The course will largely center on three (3) core learning areas: best practices in CDK4/6i therapy management, the significance of real-world evidence (RWE) in treatment decision-making, and CDK4/6i in mBC: indications, clinical data, and RWE.

This course is intended to provide information from an unbiased viewpoint on managing headaches while treating Chiari malformation with either medication or surgical therapy. This course will combine lectures, patient insights, and expert panels. It will be offered in person, digitally through Microsoft Teams, and on-demand for all paid attendees for one month following the conference. After completing this course, participants will be able to identify more precise headache care techniques and understand when surgery is necessary, use logic and reason when treating patients with Chiari malformation and headaches, and determine the prevalence of headaches and Chiari malformation in the general population.

This CME program discusses how Bruton’s tyrosine kinase inhibitors (BTKi) have improved treatment for chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), and other B-cell malignancies. However, due to adverse events and treatment resistance, many patients discontinue treatment. A new generation of BTKi with a different mechanism of action (MOA) is emerging as a possible alternative. The program presents four modules that discuss the MOAs of covalent and non-covalent BTKi, current practices for using BTKi in treatment of CLL and MCL, the efficacy and safety data for novel BTKi, and the potential role of non-covalent BTKi in future treatment plans.